A phase II study of sunitinib in patients with advanced hepatocellular carcinoma
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Dan G. Duda(Harvard University), Sam S. Yoon(Columbia University Irving Medical Center), Vivek Sindhwani(Beth Israel Deaconess Medical Center), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Emmanuelle di Tomaso(Bayer (United States)), D. Sahani(Harvard University)
Cited by 55
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k